Android app on Google Play

Sagent Pharmaceuticals, Inc. (SGNT) Reports Q2 EPS Loss of $0.37, Revenues Grow 205%

August 9, 2011 8:42 AM EDT Send to a Friend
Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) reported Q2 EPS of ($0.37), $0.16 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $32.3 million versus the consensus estimate of $34.53 million.

You May Also Be Interested In

Related Categories


Add Your Comment